#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4. Discussion
1-1	0-2	4.	_	_	_	_
1-2	3-13	Discussion	abstract	new	_	_

#Text=Within this study , we used real-time CGM ( rtCGM ) in combination with a serial analysis of blood and exhaled breath in a highly standardized setting in pediatric T1DM patients and healthy controls over a time course of nine hours .
2-1	14-20	Within	_	_	_	_
2-2	21-25	this	abstract[2]	new[2]	coref	17-25[141_2]
2-3	26-31	study	abstract[2]	new[2]	_	_
2-4	32-33	,	_	_	_	_
2-5	34-36	we	person	acc	ana	3-1
2-6	37-41	used	_	_	_	_
2-7	42-51	real-time	abstract[4]	new[4]	appos	2-10[0_4]
2-8	52-55	CGM	abstract[4]	new[4]	_	_
2-9	56-57	(	_	_	_	_
2-10	58-63	rtCGM	abstract	giv	_	_
2-11	64-65	)	_	_	_	_
2-12	66-68	in	_	_	_	_
2-13	69-80	combination	abstract[6]	new[6]	_	_
2-14	81-85	with	abstract[6]	new[6]	_	_
2-15	86-87	a	abstract[6]|abstract[7]	new[6]|new[7]	coref	5-2[45_7]
2-16	88-94	serial	abstract[6]|abstract[7]	new[6]|new[7]	_	_
2-17	95-103	analysis	abstract[6]|abstract[7]	new[6]|new[7]	_	_
2-18	104-106	of	abstract[6]|abstract[7]	new[6]|new[7]	_	_
2-19	107-112	blood	abstract[6]|abstract[7]|substance	new[6]|new[7]|new	coref	3-16
2-20	113-116	and	_	_	_	_
2-21	117-124	exhaled	abstract|abstract|abstract	new|new|new	coref|coref|coref|none|none|none	5-14[48_0]|11-9[88_0]|11-9[89_0]|2-21[0_48]|2-21[0_88]|2-21[0_89]
2-22	125-131	breath	abstract	new	coref	3-8
2-23	132-134	in	_	_	_	_
2-24	135-136	a	abstract[10]	new[10]	_	_
2-25	137-143	highly	abstract[10]	new[10]	_	_
2-26	144-156	standardized	abstract[10]	new[10]	_	_
2-27	157-164	setting	abstract[10]	new[10]	_	_
2-28	165-167	in	abstract[10]	new[10]	_	_
2-29	168-177	pediatric	abstract[10]|person[12]|abstract[13]	new[10]|new[12]|new[13]	coref|coref	11-16[92_12]|21-25[178_13]
2-30	178-182	T1DM	abstract[10]|abstract|person[12]|abstract[13]	new[10]|new|new[12]|new[13]	coref	8-5
2-31	183-191	patients	abstract[10]|person[12]|abstract[13]	new[10]|new[12]|new[13]	_	_
2-32	192-195	and	abstract[10]|abstract[13]	new[10]|new[13]	_	_
2-33	196-203	healthy	abstract[10]|abstract[13]|event[14]	new[10]|new[13]|new[14]	coref	11-20[0_14]
2-34	204-212	controls	abstract[10]|abstract[13]|event[14]	new[10]|new[13]|new[14]	_	_
2-35	213-217	over	abstract[10]|abstract[13]|event[14]	new[10]|new[13]|new[14]	_	_
2-36	218-219	a	abstract[10]|abstract[13]|event[14]|time[16]	new[10]|new[13]|new[14]|new[16]	_	_
2-37	220-224	time	abstract[10]|abstract[13]|event[14]|abstract|time[16]	new[10]|new[13]|new[14]|new|new[16]	_	_
2-38	225-231	course	abstract[10]|abstract[13]|event[14]|time[16]	new[10]|new[13]|new[14]|new[16]	_	_
2-39	232-234	of	abstract[10]|abstract[13]|event[14]|time[16]	new[10]|new[13]|new[14]|new[16]	_	_
2-40	235-239	nine	abstract[10]|abstract[13]|event[14]|time[16]|time[17]	new[10]|new[13]|new[14]|new[16]|new[17]	_	_
2-41	240-245	hours	abstract[10]|abstract[13]|event[14]|time[16]|time[17]	new[10]|new[13]|new[14]|new[16]|new[17]	_	_
2-42	246-247	.	_	_	_	_

#Text=We accumulated more than 4000 measurements of breath VOCs and interstitial glucose and almost 1000 blood samples from 44 participants .
3-1	248-250	We	person	giv	ana	5-11
3-2	251-262	accumulated	_	_	_	_
3-3	263-267	more	abstract[19]	new[19]	_	_
3-4	268-272	than	abstract[19]	new[19]	_	_
3-5	273-277	4000	abstract[19]	new[19]	_	_
3-6	278-290	measurements	abstract[19]	new[19]	_	_
3-7	291-293	of	abstract[19]	new[19]	_	_
3-8	294-300	breath	abstract[19]|abstract|object[21]	new[19]|giv|new[21]	coref|coref	4-25|7-19[67_21]
3-9	301-305	VOCs	abstract[19]|object[21]	new[19]|new[21]	_	_
3-10	306-309	and	abstract[19]	new[19]	_	_
3-11	310-322	interstitial	abstract[19]|substance[22]	new[19]|new[22]	coref	6-7[0_22]
3-12	323-330	glucose	abstract[19]|substance[22]	new[19]|new[22]	_	_
3-13	331-334	and	abstract[19]	new[19]	_	_
3-14	335-341	almost	abstract[19]|object[24]	new[19]|new[24]	_	_
3-15	342-346	1000	abstract[19]|object[24]	new[19]|new[24]	_	_
3-16	347-352	blood	abstract[19]|substance|object[24]	new[19]|giv|new[24]	coref	4-38
3-17	353-360	samples	abstract[19]|object[24]	new[19]|new[24]	_	_
3-18	361-365	from	abstract[19]|object[24]	new[19]|new[24]	_	_
3-19	366-368	44	abstract[19]|object[24]|person[25]	new[19]|new[24]|new[25]	_	_
3-20	369-381	participants	abstract[19]|object[24]|person[25]	new[19]|new[24]|new[25]	_	_
3-21	382-383	.	_	_	_	_

#Text=Standardization with respect to physical activity , the interval between meals , the type and amount of nutrients , and the restriction to alveolar breath sampling allows the generation of highly comparable diurnal profiles of breath and blood born parameters relative to the metabolic state .
4-1	384-399	Standardization	abstract[26]	new[26]	_	_
4-2	400-404	with	abstract[26]	new[26]	_	_
4-3	405-412	respect	abstract[26]|abstract[27]	new[26]|new[27]	coref	21-34[180_27]
4-4	413-415	to	abstract[26]|abstract[27]	new[26]|new[27]	_	_
4-5	416-424	physical	abstract[26]|abstract[27]|abstract[28]	new[26]|new[27]|new[28]	_	_
4-6	425-433	activity	abstract[26]|abstract[27]|abstract[28]	new[26]|new[27]|new[28]	_	_
4-7	434-435	,	_	_	_	_
4-8	436-439	the	time[29]	new[29]	coref	12-18[104_29]
4-9	440-448	interval	time[29]	new[29]	_	_
4-10	449-456	between	time[29]	new[29]	_	_
4-11	457-462	meals	time[29]|object	new[29]|new	coref	24-30
4-12	463-464	,	time[29]	new[29]	_	_
4-13	465-468	the	time[29]|abstract[31]	new[29]|new[31]	_	_
4-14	469-473	type	time[29]|abstract[31]	new[29]|new[31]	_	_
4-15	474-477	and	time[29]|abstract[31]	new[29]|new[31]	_	_
4-16	478-484	amount	time[29]|abstract[31]|abstract	new[29]|new[31]|new	coref	10-17[84_0]
4-17	485-487	of	time[29]|abstract[31]	new[29]|new[31]	_	_
4-18	488-497	nutrients	time[29]|abstract[31]|substance	new[29]|new[31]|new	_	_
4-19	498-499	,	_	_	_	_
4-20	500-503	and	_	_	_	_
4-21	504-507	the	abstract[34]	new[34]	_	_
4-22	508-519	restriction	abstract[34]	new[34]	_	_
4-23	520-522	to	abstract[34]	new[34]	_	_
4-24	523-531	alveolar	abstract[34]|object[36]	new[34]|new[36]	coref	7-11[66_36]
4-25	532-538	breath	abstract[34]|abstract|object[36]	new[34]|giv|new[36]	coref	4-36
4-26	539-547	sampling	abstract[34]|object[36]	new[34]|new[36]	_	_
4-27	548-554	allows	_	_	_	_
4-28	555-558	the	abstract[37]	new[37]	_	_
4-29	559-569	generation	abstract[37]	new[37]	_	_
4-30	570-572	of	abstract[37]	new[37]	_	_
4-31	573-579	highly	abstract[37]|object[38]	new[37]|new[38]	_	_
4-32	580-590	comparable	abstract[37]|object[38]	new[37]|new[38]	_	_
4-33	591-598	diurnal	abstract[37]|object[38]	new[37]|new[38]	_	_
4-34	599-607	profiles	abstract[37]|object[38]	new[37]|new[38]	_	_
4-35	608-610	of	abstract[37]|object[38]	new[37]|new[38]	_	_
4-36	611-617	breath	abstract[37]|object[38]|object	new[37]|new[38]|giv	coref	5-3
4-37	618-621	and	abstract[37]|object[38]	new[37]|new[38]	_	_
4-38	622-627	blood	abstract[37]|object[38]|substance	new[37]|new[38]|giv	coref	7-12
4-39	628-632	born	abstract[37]|object[38]|abstract[41]	new[37]|new[38]|new[41]	_	_
4-40	633-643	parameters	abstract[37]|object[38]|abstract[41]	new[37]|new[38]|new[41]	_	_
4-41	644-652	relative	abstract[37]|object[38]|abstract[41]	new[37]|new[38]|new[41]	_	_
4-42	653-655	to	_	_	_	_
4-43	656-659	the	abstract[43]	new[43]	_	_
4-44	660-669	metabolic	person|abstract[43]	new|new[43]	coref	20-17
4-45	670-675	state	abstract[43]	new[43]	_	_
4-46	676-677	.	_	_	_	_

#Text=For real-time breath analysis , a PTR-ToF-MS was used and we focused on the exhalation of ethanol , acetone , isopropanol , dimethyl sulfide , isoprene , pentanal , and limonene .
5-1	678-681	For	_	_	_	_
5-2	682-691	real-time	abstract[45]	giv[45]	_	_
5-3	692-698	breath	object|abstract[45]	giv|giv[45]	coref	8-15
5-4	699-707	analysis	abstract[45]	giv[45]	_	_
5-5	708-709	,	_	_	_	_
5-6	710-711	a	object[46]	new[46]	_	_
5-7	712-722	PTR-ToF-MS	object[46]	new[46]	_	_
5-8	723-726	was	_	_	_	_
5-9	727-731	used	_	_	_	_
5-10	732-735	and	_	_	_	_
5-11	736-738	we	person	giv	ana	7-3
5-12	739-746	focused	_	_	_	_
5-13	747-749	on	_	_	_	_
5-14	750-753	the	abstract[48]	new[48]	_	_
5-15	754-764	exhalation	abstract[48]	new[48]	_	_
5-16	765-767	of	abstract[48]	new[48]	_	_
5-17	768-775	ethanol	abstract[48]|substance	new[48]|new	_	_
5-18	776-777	,	abstract[48]	new[48]	_	_
5-19	778-785	acetone	abstract[48]|substance	new[48]|new	coref	8-7
5-20	786-787	,	abstract[48]	new[48]	_	_
5-21	788-799	isopropanol	abstract[48]|substance	new[48]|new	coref	18-18
5-22	800-801	,	abstract[48]	new[48]	_	_
5-23	802-810	dimethyl	abstract[48]|substance[52]	new[48]|new[52]	_	_
5-24	811-818	sulfide	abstract[48]|substance[52]	new[48]|new[52]	_	_
5-25	819-820	,	abstract[48]	new[48]	_	_
5-26	821-829	isoprene	abstract[48]|substance	new[48]|new	_	_
5-27	830-831	,	abstract[48]	new[48]	_	_
5-28	832-840	pentanal	abstract[48]|substance	new[48]|new	_	_
5-29	841-842	,	abstract[48]	new[48]	_	_
5-30	843-846	and	abstract[48]	new[48]	_	_
5-31	847-855	limonene	abstract[48]|substance	new[48]|new	_	_
5-32	856-857	.	_	_	_	_

#Text=These compounds have been linked to glucose metabolism and/or to T1DM-related comorbidities including oxidative stress .
6-1	858-863	These	substance[56]	new[56]	_	_
6-2	864-873	compounds	substance[56]	new[56]	_	_
6-3	874-878	have	_	_	_	_
6-4	879-883	been	_	_	_	_
6-5	884-890	linked	_	_	_	_
6-6	891-893	to	_	_	_	_
6-7	894-901	glucose	substance	giv	coref	12-7
6-8	902-912	metabolism	abstract	new	_	_
6-9	913-919	and/or	_	_	_	_
6-10	920-922	to	_	_	_	_
6-11	923-935	T1DM-related	abstract[59]	new[59]	_	_
6-12	936-949	comorbidities	abstract[59]	new[59]	_	_
6-13	950-959	including	abstract[59]	new[59]	_	_
6-14	960-969	oxidative	abstract[59]|abstract|abstract[61]	new[59]|new|new[61]	_	_
6-15	970-976	stress	abstract[59]|abstract[61]	new[59]|new[61]	_	_
6-16	977-978	.	_	_	_	_

#Text=Thus , we investigated the fade of classical markers via repetitive blood sampling and looked in parallel for the VOCs mentioned above .
7-1	979-983	Thus	_	_	_	_
7-2	984-985	,	_	_	_	_
7-3	986-988	we	person	giv	ana	11-5
7-4	989-1001	investigated	_	_	_	_
7-5	1002-1005	the	abstract[63]	new[63]	_	_
7-6	1006-1010	fade	abstract[63]	new[63]	_	_
7-7	1011-1013	of	abstract[63]	new[63]	_	_
7-8	1014-1023	classical	abstract[63]|abstract[64]	new[63]|new[64]	_	_
7-9	1024-1031	markers	abstract[63]|abstract[64]	new[63]|new[64]	_	_
7-10	1032-1035	via	abstract[63]|abstract[64]	new[63]|new[64]	_	_
7-11	1036-1046	repetitive	abstract[63]|abstract[64]|object[66]	new[63]|new[64]|giv[66]	coref	12-25[108_66]
7-12	1047-1052	blood	abstract[63]|abstract[64]|substance|object[66]	new[63]|new[64]|giv|giv[66]	coref	11-27
7-13	1053-1061	sampling	abstract[63]|abstract[64]|object[66]	new[63]|new[64]|giv[66]	_	_
7-14	1062-1065	and	_	_	_	_
7-15	1066-1072	looked	_	_	_	_
7-16	1073-1075	in	_	_	_	_
7-17	1076-1084	parallel	_	_	_	_
7-18	1085-1088	for	_	_	_	_
7-19	1089-1092	the	object[67]	giv[67]	_	_
7-20	1093-1097	VOCs	object[67]	giv[67]	_	_
7-21	1098-1107	mentioned	_	_	_	_
7-22	1108-1113	above	_	_	_	_
7-23	1114-1115	.	_	_	_	_

#Text=In the case of T1DM , acetone is certainly the most prominent VOC in breath and has previously been investigated under various conditions .
8-1	1116-1118	In	_	_	_	_
8-2	1119-1122	the	abstract[68]	new[68]	_	_
8-3	1123-1127	case	abstract[68]	new[68]	_	_
8-4	1128-1130	of	abstract[68]	new[68]	_	_
8-5	1131-1135	T1DM	abstract[68]|abstract	new[68]|giv	coref	11-16
8-6	1136-1137	,	_	_	_	_
8-7	1138-1145	acetone	abstract	giv	coref	8-9[71_0]
8-8	1146-1148	is	_	_	_	_
8-9	1149-1158	certainly	abstract[71]	giv[71]	coref	9-1[0_71]
8-10	1159-1162	the	abstract[71]	giv[71]	_	_
8-11	1163-1167	most	abstract[71]	giv[71]	_	_
8-12	1168-1177	prominent	abstract[71]	giv[71]	_	_
8-13	1178-1181	VOC	abstract[71]	giv[71]	_	_
8-14	1182-1184	in	abstract[71]	giv[71]	_	_
8-15	1185-1191	breath	abstract[71]|abstract	giv[71]|giv	coref	12-25
8-16	1192-1195	and	_	_	_	_
8-17	1196-1199	has	_	_	_	_
8-18	1200-1210	previously	_	_	_	_
8-19	1211-1215	been	_	_	_	_
8-20	1216-1228	investigated	_	_	_	_
8-21	1229-1234	under	_	_	_	_
8-22	1235-1242	various	abstract[73]	new[73]	coref	17-12[136_73]
8-23	1243-1253	conditions	abstract[73]	new[73]	_	_
8-24	1254-1255	.	_	_	_	_

#Text=Acetone originates from enzymatic or non-enzymatic decarboxylation of acetoacetate via Acetyl-CoA which is derived from pyruvate .
9-1	1256-1263	Acetone	substance	giv	coref	11-14[90_0]
9-2	1264-1274	originates	_	_	_	_
9-3	1275-1279	from	_	_	_	_
9-4	1280-1289	enzymatic	abstract	new	ana	10-12
9-5	1290-1292	or	_	_	_	_
9-6	1293-1306	non-enzymatic	substance[76]	new[76]	_	_
9-7	1307-1322	decarboxylation	substance[76]	new[76]	_	_
9-8	1323-1325	of	substance[76]	new[76]	_	_
9-9	1326-1338	acetoacetate	substance[76]|substance[77]	new[76]|new[77]	_	_
9-10	1339-1342	via	substance[76]|substance[77]	new[76]|new[77]	_	_
9-11	1343-1353	Acetyl-CoA	substance[76]|substance[77]|substance	new[76]|new[77]|new	_	_
9-12	1354-1359	which	_	_	_	_
9-13	1360-1362	is	_	_	_	_
9-14	1363-1370	derived	_	_	_	_
9-15	1371-1375	from	_	_	_	_
9-16	1376-1384	pyruvate	substance	new	_	_
9-17	1385-1386	.	_	_	_	_

#Text=Since the latter can originate from both glycolysis and lipolysis , it is impossible to differentiate the amount from either pathway .
10-1	1387-1392	Since	_	_	_	_
10-2	1393-1396	the	_	_	_	_
10-3	1397-1403	latter	_	_	_	_
10-4	1404-1407	can	_	_	_	_
10-5	1408-1417	originate	_	_	_	_
10-6	1418-1422	from	_	_	_	_
10-7	1423-1427	both	substance[80]	new[80]	coref	13-28[116_80]
10-8	1428-1438	glycolysis	substance[80]	new[80]	_	_
10-9	1439-1442	and	_	_	_	_
10-10	1443-1452	lipolysis	substance	new	coref	13-26
10-11	1453-1454	,	_	_	_	_
10-12	1455-1457	it	abstract	giv	_	_
10-13	1458-1460	is	_	_	_	_
10-14	1461-1471	impossible	_	_	_	_
10-15	1472-1474	to	person[83]	new[83]	_	_
10-16	1475-1488	differentiate	person[83]	new[83]	_	_
10-17	1489-1492	the	person[83]|abstract[84]	new[83]|giv[84]	_	_
10-18	1493-1499	amount	person[83]|abstract[84]	new[83]|giv[84]	_	_
10-19	1500-1504	from	person[83]|abstract[84]	new[83]|giv[84]	_	_
10-20	1505-1511	either	person[83]|abstract[84]|place[85]	new[83]|giv[84]|new[85]	coref	20-5[161_85]
10-21	1512-1519	pathway	person[83]|abstract[84]|place[85]	new[83]|giv[84]|new[85]	_	_
10-22	1520-1521	.	_	_	_	_

#Text=Regardless of this , we and others noted the significantly elevated exhalation of acetone in T1DM patients compared to controls , as well as the elevated blood levels in T1DM patients .
11-1	1522-1532	Regardless	_	_	_	_
11-2	1533-1535	of	_	_	_	_
11-3	1536-1540	this	_	_	_	_
11-4	1541-1542	,	_	_	_	_
11-5	1543-1545	we	person	giv	ana	17-25
11-6	1546-1549	and	_	_	_	_
11-7	1550-1556	others	person	new	_	_
11-8	1557-1562	noted	_	_	_	_
11-9	1563-1566	the	abstract[88]|abstract[89]	new[88]|new[89]	_	_
11-10	1567-1580	significantly	abstract[88]|abstract[89]	new[88]|new[89]	_	_
11-11	1581-1589	elevated	abstract[88]|abstract[89]	new[88]|new[89]	_	_
11-12	1590-1600	exhalation	abstract[88]|abstract[89]	new[88]|new[89]	_	_
11-13	1601-1603	of	abstract[88]|abstract[89]	new[88]|new[89]	_	_
11-14	1604-1611	acetone	abstract[88]|abstract[89]|substance[90]	new[88]|new[89]|giv[90]	coref	12-9[0_90]
11-15	1612-1614	in	abstract[88]|abstract[89]|substance[90]	new[88]|new[89]|giv[90]	_	_
11-16	1615-1619	T1DM	abstract[88]|abstract[89]|substance[90]|abstract|person[92]	new[88]|new[89]|giv[90]|giv|giv[92]	coref|coref	11-30|11-30[97_92]
11-17	1620-1628	patients	abstract[88]|abstract[89]|substance[90]|person[92]	new[88]|new[89]|giv[90]|giv[92]	_	_
11-18	1629-1637	compared	abstract[89]	new[89]	_	_
11-19	1638-1640	to	abstract[89]	new[89]	_	_
11-20	1641-1649	controls	abstract[89]|event	new[89]|giv	coref	21-28[179_0]
11-21	1650-1651	,	abstract[89]	new[89]	_	_
11-22	1652-1654	as	abstract[89]	new[89]	_	_
11-23	1655-1659	well	abstract[89]	new[89]	_	_
11-24	1660-1662	as	abstract[89]	new[89]	_	_
11-25	1663-1666	the	abstract[89]|abstract[95]	new[89]|new[95]	coref	23-12[202_95]
11-26	1667-1675	elevated	abstract[89]|abstract[95]	new[89]|new[95]	_	_
11-27	1676-1681	blood	abstract[89]|substance|abstract[95]	new[89]|giv|new[95]	coref	15-9
11-28	1682-1688	levels	abstract[89]|abstract[95]	new[89]|new[95]	_	_
11-29	1689-1691	in	abstract[89]|abstract[95]	new[89]|new[95]	_	_
11-30	1692-1696	T1DM	abstract[89]|abstract[95]|abstract|person[97]	new[89]|new[95]|giv|giv[97]	coref|coref	12-12|12-12[102_97]
11-31	1697-1705	patients	abstract[89]|abstract[95]|person[97]	new[89]|new[95]|giv[97]	_	_
11-32	1706-1707	.	_	_	_	_

#Text=However , although the concentrations of glucose and acetone correlated in T1DM patients , the time and/or the interval between food intake , and breath sampling appears to be an important confounder .
12-1	1708-1715	However	_	_	_	_
12-2	1716-1717	,	_	_	_	_
12-3	1718-1726	although	_	_	_	_
12-4	1727-1730	the	animal[98]	new[98]	coref	24-26[222_98]
12-5	1731-1745	concentrations	animal[98]	new[98]	_	_
12-6	1746-1748	of	animal[98]	new[98]	_	_
12-7	1749-1756	glucose	animal[98]|substance	new[98]|giv	coref	15-9[128_0]
12-8	1757-1760	and	animal[98]	new[98]	_	_
12-9	1761-1768	acetone	animal[98]|substance	new[98]|giv	coref	13-33
12-10	1769-1779	correlated	_	_	_	_
12-11	1780-1782	in	_	_	_	_
12-12	1783-1787	T1DM	event|person[102]	giv|giv[102]	coref|coref	19-4|19-4[151_102]
12-13	1788-1796	patients	person[102]	giv[102]	_	_
12-14	1797-1798	,	_	_	_	_
12-15	1799-1802	the	time[103]	new[103]	coref	19-23[156_103]
12-16	1803-1807	time	time[103]	new[103]	_	_
12-17	1808-1814	and/or	time[103]	new[103]	_	_
12-18	1815-1818	the	time[103]|time[104]	new[103]|giv[104]	_	_
12-19	1819-1827	interval	time[103]|time[104]	new[103]|giv[104]	_	_
12-20	1828-1835	between	time[103]|time[104]	new[103]|giv[104]	_	_
12-21	1836-1840	food	time[103]|time[104]|substance|event[106]	new[103]|giv[104]|new|new[106]	coref	14-5[120_106]
12-22	1841-1847	intake	time[103]|time[104]|event[106]	new[103]|giv[104]|new[106]	_	_
12-23	1848-1849	,	_	_	_	_
12-24	1850-1853	and	_	_	_	_
12-25	1854-1860	breath	abstract|object[108]	giv|giv[108]	coref	28-6
12-26	1861-1869	sampling	object[108]	giv[108]	_	_
12-27	1870-1877	appears	_	_	_	_
12-28	1878-1880	to	_	_	_	_
12-29	1881-1883	be	_	_	_	_
12-30	1884-1886	an	abstract[109]	new[109]	_	_
12-31	1887-1896	important	abstract[109]	new[109]	_	_
12-32	1897-1907	confounder	abstract[109]	new[109]	_	_
12-33	1908-1909	.	_	_	_	_

#Text=In the morning , when ketogenesis is high due to overnight fasting , correlations were low , most probably due to an additive effect of lipolysis and glycolysis on the formation of acetone .
13-1	1910-1912	In	_	_	_	_
13-2	1913-1916	the	time[110]	new[110]	_	_
13-3	1917-1924	morning	time[110]	new[110]	_	_
13-4	1925-1926	,	_	_	_	_
13-5	1927-1931	when	_	_	_	_
13-6	1932-1943	ketogenesis	substance	new	_	_
13-7	1944-1946	is	_	_	_	_
13-8	1947-1951	high	_	_	_	_
13-9	1952-1955	due	_	_	_	_
13-10	1956-1958	to	_	_	_	_
13-11	1959-1968	overnight	time[112]	new[112]	_	_
13-12	1969-1976	fasting	time[112]	new[112]	_	_
13-13	1977-1978	,	_	_	_	_
13-14	1979-1991	correlations	abstract	new	_	_
13-15	1992-1996	were	_	_	_	_
13-16	1997-2000	low	_	_	_	_
13-17	2001-2002	,	_	_	_	_
13-18	2003-2007	most	_	_	_	_
13-19	2008-2016	probably	_	_	_	_
13-20	2017-2020	due	_	_	_	_
13-21	2021-2023	to	_	_	_	_
13-22	2024-2026	an	abstract[114]	new[114]	_	_
13-23	2027-2035	additive	abstract[114]	new[114]	_	_
13-24	2036-2042	effect	abstract[114]	new[114]	_	_
13-25	2043-2045	of	abstract[114]	new[114]	_	_
13-26	2046-2055	lipolysis	abstract[114]|substance	new[114]|giv	coref	14-14
13-27	2056-2059	and	abstract[114]	new[114]	_	_
13-28	2060-2070	glycolysis	abstract[114]|substance[116]	new[114]|giv[116]	_	_
13-29	2071-2073	on	abstract[114]|substance[116]	new[114]|giv[116]	_	_
13-30	2074-2077	the	abstract[114]|substance[116]|event[117]	new[114]|giv[116]|new[117]	_	_
13-31	2078-2087	formation	abstract[114]|substance[116]|event[117]	new[114]|giv[116]|new[117]	_	_
13-32	2088-2090	of	abstract[114]|substance[116]|event[117]	new[114]|giv[116]|new[117]	_	_
13-33	2091-2098	acetone	abstract[114]|substance[116]|event[117]|substance	new[114]|giv[116]|new[117]|giv	coref	15-7
13-34	2099-2100	.	_	_	_	_

#Text=Correlation improved markedly after a moderate intake of carbohydrates and insulin-related inhibition of lipolysis .
14-1	2101-2112	Correlation	abstract	new	coref	15-5[125_0]
14-2	2113-2121	improved	_	_	_	_
14-3	2122-2130	markedly	_	_	_	_
14-4	2131-2136	after	_	_	_	_
14-5	2137-2138	a	event[120]	giv[120]	coref	29-25[273_120]
14-6	2139-2147	moderate	event[120]	giv[120]	_	_
14-7	2148-2154	intake	event[120]	giv[120]	_	_
14-8	2155-2157	of	event[120]	giv[120]	_	_
14-9	2158-2171	carbohydrates	event[120]|substance	giv[120]|new	coref	28-36
14-10	2172-2175	and	event[120]	giv[120]	_	_
14-11	2176-2191	insulin-related	event[120]|abstract[122]	giv[120]|new[122]	_	_
14-12	2192-2202	inhibition	event[120]|abstract[122]	giv[120]|new[122]	_	_
14-13	2203-2205	of	event[120]|abstract[122]	giv[120]|new[122]	_	_
14-14	2206-2215	lipolysis	event[120]|abstract[122]|substance	giv[120]|new[122]|giv	_	_
14-15	2216-2217	.	_	_	_	_

#Text=In the afternoon , correlation between acetone and blood glucose remained low .
15-1	2218-2220	In	_	_	_	_
15-2	2221-2224	the	time[124]	new[124]	_	_
15-3	2225-2234	afternoon	time[124]	new[124]	_	_
15-4	2235-2236	,	_	_	_	_
15-5	2237-2248	correlation	abstract[125]	giv[125]	ana	16-1[0_125]
15-6	2249-2256	between	abstract[125]	giv[125]	_	_
15-7	2257-2264	acetone	abstract[125]|substance	giv[125]|giv	coref	17-6[133_0]
15-8	2265-2268	and	abstract[125]	giv[125]	_	_
15-9	2269-2274	blood	abstract[125]|substance|substance[128]	giv[125]|giv|giv[128]	coref|coref	17-8|17-8[135_128]
15-10	2275-2282	glucose	abstract[125]|substance[128]	giv[125]|giv[128]	_	_
15-11	2283-2291	remained	_	_	_	_
15-12	2292-2295	low	_	_	_	_
15-13	2296-2297	.	_	_	_	_

#Text=This was most probably due to postprandial hyperglycemia .
16-1	2298-2302	This	abstract	giv	coref	17-3[132_0]
16-2	2303-2306	was	_	_	_	_
16-3	2307-2311	most	_	_	_	_
16-4	2312-2320	probably	_	_	_	_
16-5	2321-2324	due	_	_	_	_
16-6	2325-2327	to	_	_	_	_
16-7	2328-2340	postprandial	abstract|abstract[131]	new|new[131]	coref	25-19[230_131]
16-8	2341-2354	hyperglycemia	abstract[131]	new[131]	_	_
16-9	2355-2356	.	_	_	_	_

#Text=Thus , a correlation of acetone with blood glucose is difficult even under healthy conditions and the time-resolved calculation of the correlation coefficients in our study strengthen this observation .
17-1	2357-2361	Thus	_	_	_	_
17-2	2362-2363	,	_	_	_	_
17-3	2364-2365	a	abstract[132]	giv[132]	coref	17-22[0_132]
17-4	2366-2377	correlation	abstract[132]	giv[132]	_	_
17-5	2378-2380	of	abstract[132]	giv[132]	_	_
17-6	2381-2388	acetone	abstract[132]|substance[133]	giv[132]|giv[133]	coref	18-16[148_133]
17-7	2389-2393	with	abstract[132]|substance[133]	giv[132]|giv[133]	_	_
17-8	2394-2399	blood	abstract[132]|substance[133]|substance|substance[135]	giv[132]|giv[133]|giv|giv[135]	coref	23-12
17-9	2400-2407	glucose	abstract[132]|substance[133]|substance[135]	giv[132]|giv[133]|giv[135]	_	_
17-10	2408-2410	is	_	_	_	_
17-11	2411-2420	difficult	_	_	_	_
17-12	2421-2425	even	abstract[136]	giv[136]	coref	23-2[197_136]
17-13	2426-2431	under	abstract[136]	giv[136]	_	_
17-14	2432-2439	healthy	abstract[136]	giv[136]	_	_
17-15	2440-2450	conditions	abstract[136]	giv[136]	_	_
17-16	2451-2454	and	_	_	_	_
17-17	2455-2458	the	abstract[137]	new[137]	_	_
17-18	2459-2472	time-resolved	abstract[137]	new[137]	_	_
17-19	2473-2484	calculation	abstract[137]	new[137]	_	_
17-20	2485-2487	of	abstract[137]	new[137]	_	_
17-21	2488-2491	the	abstract[137]|abstract[139]	new[137]|new[139]	coref	19-26[158_139]
17-22	2492-2503	correlation	abstract[137]|abstract|abstract[139]	new[137]|giv|new[139]	coref	19-26
17-23	2504-2516	coefficients	abstract[137]|abstract[139]	new[137]|new[139]	_	_
17-24	2517-2519	in	abstract[137]|abstract[139]	new[137]|new[139]	_	_
17-25	2520-2523	our	abstract[137]|abstract[139]|person|abstract[141]	new[137]|new[139]|giv|giv[141]	_	_
17-26	2524-2529	study	abstract[137]|abstract[139]|abstract[141]	new[137]|new[139]|giv[141]	_	_
17-27	2530-2540	strengthen	_	_	_	_
17-28	2541-2545	this	abstract[142]	new[142]	_	_
17-29	2546-2557	observation	abstract[142]	new[142]	_	_
17-30	2558-2559	.	_	_	_	_

#Text=Furthermore , the impact of hepatic alcohol dehydrogenase , i. e. , the reduction of acetone to isopropanol , has to be considered .
18-1	2560-2571	Furthermore	_	_	_	_
18-2	2572-2573	,	_	_	_	_
18-3	2574-2577	the	abstract[143]	new[143]	_	_
18-4	2578-2584	impact	abstract[143]	new[143]	_	_
18-5	2585-2587	of	abstract[143]	new[143]	_	_
18-6	2588-2595	hepatic	abstract[143]|substance|abstract[146]	new[143]|new|new[146]	_	_
18-7	2596-2603	alcohol	abstract[143]|substance|abstract[146]	new[143]|new|new[146]	_	_
18-8	2604-2617	dehydrogenase	abstract[143]|abstract[146]	new[143]|new[146]	_	_
18-9	2618-2619	,	abstract[143]	new[143]	_	_
18-10	2620-2622	i.	abstract[143]	new[143]	_	_
18-11	2623-2625	e.	abstract[143]	new[143]	_	_
18-12	2626-2627	,	abstract[143]	new[143]	_	_
18-13	2628-2631	the	abstract[143]|event[147]	new[143]|new[147]	_	_
18-14	2632-2641	reduction	abstract[143]|event[147]	new[143]|new[147]	_	_
18-15	2642-2644	of	abstract[143]|event[147]	new[143]|new[147]	_	_
18-16	2645-2652	acetone	abstract[143]|event[147]|substance[148]	new[143]|new[147]|giv[148]	coref	19-33[0_148]
18-17	2653-2655	to	abstract[143]|event[147]|substance[148]	new[143]|new[147]|giv[148]	_	_
18-18	2656-2667	isopropanol	abstract[143]|event[147]|substance[148]|substance	new[143]|new[147]|giv[148]|giv	coref	19-7[152_0]
18-19	2668-2669	,	_	_	_	_
18-20	2670-2673	has	_	_	_	_
18-21	2674-2676	to	_	_	_	_
18-22	2677-2679	be	_	_	_	_
18-23	2680-2690	considered	_	_	_	_
18-24	2691-2692	.	_	_	_	_

#Text=In fact , T1DM patients exhaled significantly more isopropanol than their healthy peers and both , the diurnal profile as well as the time resolved correlation coefficients , closely resembled that of acetone .
19-1	2693-2695	In	_	_	_	_
19-2	2696-2700	fact	_	_	_	_
19-3	2701-2702	,	_	_	_	_
19-4	2703-2707	T1DM	abstract|person[151]	giv|giv[151]	ana|coref	19-11[0_151]|20-8
19-5	2708-2716	patients	person[151]	giv[151]	_	_
19-6	2717-2724	exhaled	_	_	_	_
19-7	2725-2738	significantly	substance[152]	giv[152]	_	_
19-8	2739-2743	more	substance[152]	giv[152]	_	_
19-9	2744-2755	isopropanol	substance[152]	giv[152]	_	_
19-10	2756-2760	than	substance[152]	giv[152]	_	_
19-11	2761-2766	their	substance[152]|person|person[154]	giv[152]|giv|new[154]	coref	20-8[163_0]
19-12	2767-2774	healthy	substance[152]|person[154]	giv[152]|new[154]	_	_
19-13	2775-2780	peers	substance[152]|person[154]	giv[152]|new[154]	_	_
19-14	2781-2784	and	substance[152]	giv[152]	_	_
19-15	2785-2789	both	substance[152]	giv[152]	_	_
19-16	2790-2791	,	substance[152]	giv[152]	_	_
19-17	2792-2795	the	substance[152]|abstract[155]	giv[152]|new[155]	_	_
19-18	2796-2803	diurnal	substance[152]|abstract[155]	giv[152]|new[155]	_	_
19-19	2804-2811	profile	substance[152]|abstract[155]	giv[152]|new[155]	_	_
19-20	2812-2814	as	_	_	_	_
19-21	2815-2819	well	_	_	_	_
19-22	2820-2822	as	_	_	_	_
19-23	2823-2826	the	time[156]	giv[156]	coref	23-28[208_156]
19-24	2827-2831	time	time[156]	giv[156]	_	_
19-25	2832-2840	resolved	_	_	_	_
19-26	2841-2852	correlation	abstract|abstract[158]	giv|giv[158]	coref	28-1[251_0]
19-27	2853-2865	coefficients	abstract[158]	giv[158]	_	_
19-28	2866-2867	,	_	_	_	_
19-29	2868-2875	closely	_	_	_	_
19-30	2876-2885	resembled	_	_	_	_
19-31	2886-2890	that	_	_	_	_
19-32	2891-2893	of	_	_	_	_
19-33	2894-2901	acetone	substance	giv	coref	20-13
19-34	2902-2903	.	_	_	_	_

#Text=Thus , activation of this pathway in T1DM patients may attribute to acetone elimination and indicate metabolic adaptation .
20-1	2904-2908	Thus	_	_	_	_
20-2	2909-2910	,	_	_	_	_
20-3	2911-2921	activation	abstract[160]	new[160]	_	_
20-4	2922-2924	of	abstract[160]	new[160]	_	_
20-5	2925-2929	this	abstract[160]|place[161]	new[160]|giv[161]	ana	22-1[0_161]
20-6	2930-2937	pathway	abstract[160]|place[161]	new[160]|giv[161]	_	_
20-7	2938-2940	in	abstract[160]|place[161]	new[160]|giv[161]	_	_
20-8	2941-2945	T1DM	abstract[160]|place[161]|abstract|person[163]	new[160]|giv[161]|giv|giv[163]	coref|coref	21-25|21-25[177_163]
20-9	2946-2954	patients	abstract[160]|place[161]|person[163]	new[160]|giv[161]|giv[163]	_	_
20-10	2955-2958	may	_	_	_	_
20-11	2959-2968	attribute	_	_	_	_
20-12	2969-2971	to	_	_	_	_
20-13	2972-2979	acetone	substance|abstract[165]	giv|new[165]	_	_
20-14	2980-2991	elimination	abstract[165]	new[165]	_	_
20-15	2992-2995	and	_	_	_	_
20-16	2996-3004	indicate	_	_	_	_
20-17	3005-3014	metabolic	person|abstract[167]	giv|new[167]	_	_
20-18	3015-3025	adaptation	abstract[167]	new[167]	_	_
20-19	3026-3027	.	_	_	_	_

#Text=The shape of the normalized diurnal profiles of glucose , insulin , glucagon , lipids , leptin , and slepR are fairly comparable in T1DM patients and healthy controls , but differ with respect to slope and inter-individual variability , i. e. , changes over time are faster in controls while inter-individual variability is much greater in T1DM patients .
21-1	3028-3031	The	abstract[168]	new[168]	_	_
21-2	3032-3037	shape	abstract[168]	new[168]	_	_
21-3	3038-3040	of	abstract[168]	new[168]	_	_
21-4	3041-3044	the	abstract[168]|abstract[169]	new[168]|new[169]	coref	28-13[257_169]
21-5	3045-3055	normalized	abstract[168]|abstract[169]	new[168]|new[169]	_	_
21-6	3056-3063	diurnal	abstract[168]|abstract[169]	new[168]|new[169]	_	_
21-7	3064-3072	profiles	abstract[168]|abstract[169]	new[168]|new[169]	_	_
21-8	3073-3075	of	abstract[168]|abstract[169]	new[168]|new[169]	_	_
21-9	3076-3083	glucose	abstract[168]|abstract[169]|substance	new[168]|new[169]|new	coref	22-29
21-10	3084-3085	,	abstract[168]|abstract[169]	new[168]|new[169]	_	_
21-11	3086-3093	insulin	abstract[168]|abstract[169]|substance	new[168]|new[169]|new	coref	22-17
21-12	3094-3095	,	abstract[168]|abstract[169]	new[168]|new[169]	_	_
21-13	3096-3104	glucagon	abstract[168]|abstract[169]|substance	new[168]|new[169]|new	coref	22-31
21-14	3105-3106	,	abstract[168]|abstract[169]	new[168]|new[169]	_	_
21-15	3107-3113	lipids	abstract[168]|abstract[169]|substance	new[168]|new[169]|new	_	_
21-16	3114-3115	,	abstract[168]|abstract[169]	new[168]|new[169]	_	_
21-17	3116-3122	leptin	abstract[168]|abstract[169]|substance	new[168]|new[169]|new	_	_
21-18	3123-3124	,	abstract[168]|abstract[169]	new[168]|new[169]	_	_
21-19	3125-3128	and	abstract[168]|abstract[169]	new[168]|new[169]	_	_
21-20	3129-3134	slepR	abstract[168]|abstract[169]|substance	new[168]|new[169]|new	_	_
21-21	3135-3138	are	_	_	_	_
21-22	3139-3145	fairly	_	_	_	_
21-23	3146-3156	comparable	_	_	_	_
21-24	3157-3159	in	_	_	_	_
21-25	3160-3164	T1DM	abstract|person[177]|abstract[178]	giv|giv[177]|giv[178]	coref|coref|coref	21-58|21-58[187_177]|30-29[287_178]
21-26	3165-3173	patients	person[177]|abstract[178]	giv[177]|giv[178]	_	_
21-27	3174-3177	and	abstract[178]	giv[178]	_	_
21-28	3178-3185	healthy	abstract[178]|event[179]	giv[178]|giv[179]	coref	21-50[0_179]
21-29	3186-3194	controls	abstract[178]|event[179]	giv[178]|giv[179]	_	_
21-30	3195-3196	,	_	_	_	_
21-31	3197-3200	but	_	_	_	_
21-32	3201-3207	differ	_	_	_	_
21-33	3208-3212	with	_	_	_	_
21-34	3213-3220	respect	abstract[180]	giv[180]	coref	30-23[283_180]
21-35	3221-3223	to	abstract[180]	giv[180]	_	_
21-36	3224-3229	slope	abstract[180]|abstract	giv[180]|new	_	_
21-37	3230-3233	and	abstract[180]	giv[180]	_	_
21-38	3234-3250	inter-individual	abstract[180]|abstract[182]	giv[180]|new[182]	coref	21-52[185_182]
21-39	3251-3262	variability	abstract[180]|abstract[182]	giv[180]|new[182]	_	_
21-40	3263-3264	,	abstract[180]	giv[180]	_	_
21-41	3265-3267	i.	abstract[180]	giv[180]	_	_
21-42	3268-3270	e.	abstract[180]	giv[180]	_	_
21-43	3271-3272	,	_	_	_	_
21-44	3273-3280	changes	abstract[183]	new[183]	_	_
21-45	3281-3285	over	abstract[183]	new[183]	_	_
21-46	3286-3290	time	abstract[183]	new[183]	_	_
21-47	3291-3294	are	_	_	_	_
21-48	3295-3301	faster	_	_	_	_
21-49	3302-3304	in	_	_	_	_
21-50	3305-3313	controls	event	giv	coref	30-32
21-51	3314-3319	while	_	_	_	_
21-52	3320-3336	inter-individual	abstract[185]	giv[185]	_	_
21-53	3337-3348	variability	abstract[185]	giv[185]	_	_
21-54	3349-3351	is	_	_	_	_
21-55	3352-3356	much	_	_	_	_
21-56	3357-3364	greater	_	_	_	_
21-57	3365-3367	in	_	_	_	_
21-58	3368-3372	T1DM	abstract|person[187]	giv|giv[187]	coref|coref	25-5|25-5[226_187]
21-59	3373-3381	patients	person[187]	giv[187]	_	_
21-60	3382-3383	.	_	_	_	_

#Text=This might , at least in part , be due to the limited abilities of pharmaceutical insulin preparations to mimic the physiological interplay between insulin-induced cellular uptake of glucose and glucagon secretion .
22-1	3384-3388	This	place	giv	_	_
22-2	3389-3394	might	_	_	_	_
22-3	3395-3396	,	_	_	_	_
22-4	3397-3399	at	_	_	_	_
22-5	3400-3405	least	_	_	_	_
22-6	3406-3408	in	_	_	_	_
22-7	3409-3413	part	_	_	_	_
22-8	3414-3415	,	_	_	_	_
22-9	3416-3418	be	_	_	_	_
22-10	3419-3422	due	_	_	_	_
22-11	3423-3425	to	_	_	_	_
22-12	3426-3429	the	abstract[189]	new[189]	_	_
22-13	3430-3437	limited	abstract[189]	new[189]	_	_
22-14	3438-3447	abilities	abstract[189]	new[189]	_	_
22-15	3448-3450	of	abstract[189]	new[189]	_	_
22-16	3451-3465	pharmaceutical	abstract[189]|object[191]	new[189]|new[191]	_	_
22-17	3466-3473	insulin	abstract[189]|object|object[191]	new[189]|giv|new[191]	coref	23-5
22-18	3474-3486	preparations	abstract[189]|object[191]	new[189]|new[191]	_	_
22-19	3487-3489	to	_	_	_	_
22-20	3490-3495	mimic	_	_	_	_
22-21	3496-3499	the	abstract[192]	new[192]	_	_
22-22	3500-3513	physiological	abstract[192]	new[192]	_	_
22-23	3514-3523	interplay	abstract[192]	new[192]	_	_
22-24	3524-3531	between	abstract[192]	new[192]	_	_
22-25	3532-3547	insulin-induced	abstract[192]|abstract[193]	new[192]|new[193]	coref	23-18[204_193]
22-26	3548-3556	cellular	abstract[192]|abstract[193]	new[192]|new[193]	_	_
22-27	3557-3563	uptake	abstract[192]|abstract[193]	new[192]|new[193]	_	_
22-28	3564-3566	of	abstract[192]|abstract[193]	new[192]|new[193]	_	_
22-29	3567-3574	glucose	abstract[192]|abstract[193]|substance	new[192]|new[193]|giv	coref	23-13
22-30	3575-3578	and	abstract[192]|abstract[193]	new[192]|new[193]	_	_
22-31	3579-3587	glucagon	abstract[192]|abstract[193]|abstract|substance[196]	new[192]|new[193]|giv|new[196]	coref|coref	23-25|23-24[207_196]
22-32	3588-3597	secretion	abstract[192]|abstract[193]|substance[196]	new[192]|new[193]|new[196]	_	_
22-33	3598-3599	.	_	_	_	_

#Text=Under physiological conditions , insulin is secreted in response to increasing blood glucose levels and by inducing cellular glucose uptake and inhibition of pancreatic glucagon secretion at the same time it contributes to maintenance of glucose homeostasis .
23-1	3600-3605	Under	_	_	_	_
23-2	3606-3619	physiological	abstract[197]	giv[197]	_	_
23-3	3620-3630	conditions	abstract[197]	giv[197]	_	_
23-4	3631-3632	,	_	_	_	_
23-5	3633-3640	insulin	substance	giv	coref	24-26
23-6	3641-3643	is	_	_	_	_
23-7	3644-3652	secreted	_	_	_	_
23-8	3653-3655	in	_	_	_	_
23-9	3656-3664	response	abstract	new	_	_
23-10	3665-3667	to	_	_	_	_
23-11	3668-3678	increasing	_	_	_	_
23-12	3679-3684	blood	substance|abstract[202]	giv|giv[202]	coref|coref	24-10|27-17[241_202]
23-13	3685-3692	glucose	substance|abstract[202]	giv|giv[202]	coref	23-19
23-14	3693-3699	levels	abstract[202]	giv[202]	_	_
23-15	3700-3703	and	_	_	_	_
23-16	3704-3706	by	_	_	_	_
23-17	3707-3715	inducing	_	_	_	_
23-18	3716-3724	cellular	abstract[204]	giv[204]	_	_
23-19	3725-3732	glucose	substance|abstract[204]	giv|giv[204]	coref	23-36
23-20	3733-3739	uptake	abstract[204]	giv[204]	_	_
23-21	3740-3743	and	_	_	_	_
23-22	3744-3754	inhibition	event[205]	new[205]	_	_
23-23	3755-3757	of	event[205]	new[205]	_	_
23-24	3758-3768	pancreatic	event[205]|substance[207]	new[205]|giv[207]	ana	23-31[0_207]
23-25	3769-3777	glucagon	event[205]|abstract|substance[207]	new[205]|giv|giv[207]	coref	24-7
23-26	3778-3787	secretion	event[205]|substance[207]	new[205]|giv[207]	_	_
23-27	3788-3790	at	event[205]|substance[207]	new[205]|giv[207]	_	_
23-28	3791-3794	the	event[205]|substance[207]|time[208]	new[205]|giv[207]|giv[208]	coref	28-26[260_208]
23-29	3795-3799	same	event[205]|substance[207]|time[208]	new[205]|giv[207]|giv[208]	_	_
23-30	3800-3804	time	event[205]|substance[207]|time[208]	new[205]|giv[207]|giv[208]	_	_
23-31	3805-3807	it	substance	giv	_	_
23-32	3808-3819	contributes	_	_	_	_
23-33	3820-3822	to	_	_	_	_
23-34	3823-3834	maintenance	abstract[210]	new[210]	_	_
23-35	3835-3837	of	abstract[210]	new[210]	_	_
23-36	3838-3845	glucose	abstract[210]|substance|abstract[212]	new[210]|giv|new[212]	coref	24-18
23-37	3846-3857	homeostasis	abstract[210]|abstract[212]	new[210]|new[212]	_	_
23-38	3858-3859	.	_	_	_	_

#Text=Thus , in healthy individuals , glucagon concentration in blood remains constant as long as the blood glucose concentration stays within the normal range and insulin concentrations peak after meals .
24-1	3860-3864	Thus	_	_	_	_
24-2	3865-3866	,	_	_	_	_
24-3	3867-3869	in	_	_	_	_
24-4	3870-3877	healthy	person[213]	new[213]	_	_
24-5	3878-3889	individuals	person[213]	new[213]	_	_
24-6	3890-3891	,	_	_	_	_
24-7	3892-3900	glucagon	abstract|abstract[215]	giv|new[215]	coref|coref	24-16[219_215]|25-7
24-8	3901-3914	concentration	abstract[215]	new[215]	_	_
24-9	3915-3917	in	abstract[215]	new[215]	_	_
24-10	3918-3923	blood	abstract[215]|substance	new[215]|giv	coref	24-17
24-11	3924-3931	remains	_	_	_	_
24-12	3932-3940	constant	_	_	_	_
24-13	3941-3943	as	_	_	_	_
24-14	3944-3948	long	_	_	_	_
24-15	3949-3951	as	_	_	_	_
24-16	3952-3955	the	abstract[219]	giv[219]	coref	28-14[0_219]
24-17	3956-3961	blood	substance|abstract[219]	giv|giv[219]	_	_
24-18	3962-3969	glucose	substance|abstract[219]	giv|giv[219]	_	_
24-19	3970-3983	concentration	abstract[219]	giv[219]	_	_
24-20	3984-3989	stays	_	_	_	_
24-21	3990-3996	within	_	_	_	_
24-22	3997-4000	the	abstract[220]	new[220]	_	_
24-23	4001-4007	normal	abstract[220]	new[220]	_	_
24-24	4008-4013	range	abstract[220]	new[220]	_	_
24-25	4014-4017	and	_	_	_	_
24-26	4018-4025	insulin	substance|animal[222]	giv|giv[222]	coref|coref	25-7[228_222]|27-30
24-27	4026-4040	concentrations	animal[222]	giv[222]	_	_
24-28	4041-4045	peak	_	_	_	_
24-29	4046-4051	after	_	_	_	_
24-30	4052-4057	meals	object	giv	coref	25-12[229_0]
24-31	4058-4059	.	_	_	_	_

#Text=In contrast , in T1DM patients glucagon concentrations remain partially elevated even after meals and most likely aggravate postprandial hyperglycemia .
25-1	4060-4062	In	_	_	_	_
25-2	4063-4071	contrast	abstract	new	_	_
25-3	4072-4073	,	_	_	_	_
25-4	4074-4076	in	_	_	_	_
25-5	4077-4081	T1DM	abstract|person[226]	giv|giv[226]	coref|coref	27-49|27-48[250_226]
25-6	4082-4090	patients	person[226]	giv[226]	_	_
25-7	4091-4099	glucagon	substance|animal[228]	giv|giv[228]	coref	31-16[292_228]
25-8	4100-4114	concentrations	animal[228]	giv[228]	_	_
25-9	4115-4121	remain	_	_	_	_
25-10	4122-4131	partially	_	_	_	_
25-11	4132-4140	elevated	_	_	_	_
25-12	4141-4145	even	object[229]	giv[229]	_	_
25-13	4146-4151	after	object[229]	giv[229]	_	_
25-14	4152-4157	meals	object[229]	giv[229]	_	_
25-15	4158-4161	and	_	_	_	_
25-16	4162-4166	most	_	_	_	_
25-17	4167-4173	likely	_	_	_	_
25-18	4174-4183	aggravate	_	_	_	_
25-19	4184-4196	postprandial	abstract[230]	giv[230]	coref	30-14[281_230]
25-20	4197-4210	hyperglycemia	abstract[230]	giv[230]	_	_
25-21	4211-4212	.	_	_	_	_

#Text=The latter , especially in concert with dyslipidemia is considered as a relevant contributor to the overall increased risk for the development of cardiovascular disease .
26-1	4213-4216	The	_	_	_	_
26-2	4217-4223	latter	_	_	_	_
26-3	4224-4225	,	_	_	_	_
26-4	4226-4236	especially	event[231]	new[231]	_	_
26-5	4237-4239	in	event[231]	new[231]	_	_
26-6	4240-4247	concert	event[231]	new[231]	_	_
26-7	4248-4252	with	event[231]	new[231]	_	_
26-8	4253-4265	dyslipidemia	event[231]|abstract	new[231]|new	_	_
26-9	4266-4268	is	_	_	_	_
26-10	4269-4279	considered	_	_	_	_
26-11	4280-4282	as	_	_	_	_
26-12	4283-4284	a	_	_	_	_
26-13	4285-4293	relevant	_	_	_	_
26-14	4294-4305	contributor	_	_	_	_
26-15	4306-4308	to	_	_	_	_
26-16	4309-4312	the	abstract[233]	new[233]	_	_
26-17	4313-4320	overall	abstract[233]	new[233]	_	_
26-18	4321-4330	increased	abstract[233]	new[233]	_	_
26-19	4331-4335	risk	abstract[233]	new[233]	_	_
26-20	4336-4339	for	abstract[233]	new[233]	_	_
26-21	4340-4343	the	abstract[233]|event[234]	new[233]|new[234]	_	_
26-22	4344-4355	development	abstract[233]|event[234]	new[233]|new[234]	_	_
26-23	4356-4358	of	abstract[233]|event[234]	new[233]|new[234]	_	_
26-24	4359-4373	cardiovascular	abstract[233]|event[234]|abstract|abstract[236]	new[233]|new[234]|new|new[236]	_	_
26-25	4374-4381	disease	abstract[233]|event[234]|abstract[236]	new[233]|new[234]|new[236]	_	_
26-26	4382-4383	.	_	_	_	_

#Text=On the one hand , poor glycemic control is likely to result in elevated cholesterol and triglyceride levels , on the other hand , peripheral hyperinsulinemia secondary to subcutaneous insulin administration contribute to qualitative abnormalities of lipid metabolism as well and this has recently been shown in young T1DM patients .
27-1	4384-4386	On	_	_	_	_
27-2	4387-4390	the	_	_	_	_
27-3	4391-4394	one	_	_	_	_
27-4	4395-4399	hand	_	_	_	_
27-5	4400-4401	,	_	_	_	_
27-6	4402-4406	poor	abstract[238]	new[238]	_	_
27-7	4407-4415	glycemic	abstract|abstract[238]	new|new[238]	_	_
27-8	4416-4423	control	abstract[238]	new[238]	_	_
27-9	4424-4426	is	_	_	_	_
27-10	4427-4433	likely	_	_	_	_
27-11	4434-4436	to	_	_	_	_
27-12	4437-4443	result	_	_	_	_
27-13	4444-4446	in	_	_	_	_
27-14	4447-4455	elevated	substance[239]	new[239]	_	_
27-15	4456-4467	cholesterol	substance[239]	new[239]	_	_
27-16	4468-4471	and	_	_	_	_
27-17	4472-4484	triglyceride	abstract|abstract[241]	new|giv[241]	_	_
27-18	4485-4491	levels	abstract[241]	giv[241]	_	_
27-19	4492-4493	,	_	_	_	_
27-20	4494-4496	on	_	_	_	_
27-21	4497-4500	the	_	_	_	_
27-22	4501-4506	other	_	_	_	_
27-23	4507-4511	hand	_	_	_	_
27-24	4512-4513	,	_	_	_	_
27-25	4514-4524	peripheral	abstract[242]	new[242]	_	_
27-26	4525-4541	hyperinsulinemia	abstract[242]	new[242]	_	_
27-27	4542-4551	secondary	abstract[242]	new[242]	_	_
27-28	4552-4554	to	_	_	_	_
27-29	4555-4567	subcutaneous	event[244]	new[244]	ana	27-42[0_244]
27-30	4568-4575	insulin	substance|event[244]	giv|new[244]	_	_
27-31	4576-4590	administration	event[244]	new[244]	_	_
27-32	4591-4601	contribute	_	_	_	_
27-33	4602-4604	to	_	_	_	_
27-34	4605-4616	qualitative	event[245]	new[245]	_	_
27-35	4617-4630	abnormalities	event[245]	new[245]	_	_
27-36	4631-4633	of	event[245]	new[245]	_	_
27-37	4634-4639	lipid	event[245]|object|abstract[247]	new[245]|new|new[247]	_	_
27-38	4640-4650	metabolism	event[245]|abstract[247]	new[245]|new[247]	_	_
27-39	4651-4653	as	_	_	_	_
27-40	4654-4658	well	_	_	_	_
27-41	4659-4662	and	_	_	_	_
27-42	4663-4667	this	event	giv	_	_
27-43	4668-4671	has	_	_	_	_
27-44	4672-4680	recently	_	_	_	_
27-45	4681-4685	been	_	_	_	_
27-46	4686-4691	shown	_	_	_	_
27-47	4692-4694	in	_	_	_	_
27-48	4695-4700	young	person[250]	giv[250]	coref	30-29[286_250]
27-49	4701-4705	T1DM	abstract|person[250]	giv|giv[250]	coref	30-29
27-50	4706-4714	patients	person[250]	giv[250]	_	_
27-51	4715-4716	.	_	_	_	_

#Text=Albeit no clear correlation between breath ethanol and serum triglycerides exists , the concentration profiles were quite similar , especially in the second half of the examination period , i. e. , after challenge with carbohydrates ( pasta ) at lunch .
28-1	4717-4723	Albeit	abstract[251]	giv[251]	_	_
28-2	4724-4726	no	abstract[251]	giv[251]	_	_
28-3	4727-4732	clear	abstract[251]	giv[251]	_	_
28-4	4733-4744	correlation	abstract[251]	giv[251]	_	_
28-5	4745-4752	between	abstract[251]	giv[251]	_	_
28-6	4753-4759	breath	abstract[251]|abstract|substance[253]	giv[251]|giv|new[253]	coref|coref	29-1[265_253]|29-19
28-7	4760-4767	ethanol	abstract[251]|substance[253]	giv[251]|new[253]	_	_
28-8	4768-4771	and	abstract[251]	giv[251]	_	_
28-9	4772-4777	serum	abstract[251]|abstract|substance[255]	giv[251]|new|new[255]	_	_
28-10	4778-4791	triglycerides	abstract[251]|substance[255]	giv[251]|new[255]	_	_
28-11	4792-4798	exists	_	_	_	_
28-12	4799-4800	,	_	_	_	_
28-13	4801-4804	the	abstract[257]	giv[257]	_	_
28-14	4805-4818	concentration	abstract|abstract[257]	giv|giv[257]	_	_
28-15	4819-4827	profiles	abstract[257]	giv[257]	_	_
28-16	4828-4832	were	_	_	_	_
28-17	4833-4838	quite	_	_	_	_
28-18	4839-4846	similar	_	_	_	_
28-19	4847-4848	,	_	_	_	_
28-20	4849-4859	especially	time[258]	new[258]	_	_
28-21	4860-4862	in	time[258]	new[258]	_	_
28-22	4863-4866	the	time[258]	new[258]	_	_
28-23	4867-4873	second	time[258]	new[258]	_	_
28-24	4874-4878	half	time[258]	new[258]	_	_
28-25	4879-4881	of	time[258]	new[258]	_	_
28-26	4882-4885	the	time[258]|time[260]	new[258]|giv[260]	_	_
28-27	4886-4897	examination	time[258]|event|time[260]	new[258]|new|giv[260]	_	_
28-28	4898-4904	period	time[258]|time[260]	new[258]|giv[260]	_	_
28-29	4905-4906	,	_	_	_	_
28-30	4907-4909	i.	_	_	_	_
28-31	4910-4912	e.	_	_	_	_
28-32	4913-4914	,	_	_	_	_
28-33	4915-4920	after	_	_	_	_
28-34	4921-4930	challenge	event[261]	new[261]	_	_
28-35	4931-4935	with	event[261]	new[261]	_	_
28-36	4936-4949	carbohydrates	event[261]|substance	new[261]|giv	appos	28-38
28-37	4950-4951	(	_	_	_	_
28-38	4952-4957	pasta	substance	giv	coref	29-14
28-39	4958-4959	)	_	_	_	_
28-40	4960-4962	at	_	_	_	_
28-41	4963-4968	lunch	event	new	coref	30-6
28-42	4969-4970	.	_	_	_	_

#Text=Endogenous ethanol is supposed to originate from intestinal bacterial activity via fermentation of carbohydrates , i. e. , breath ethanol increase is due to the intake with subsequent digestion of carbohydrates and the intestinal microbiota .
29-1	4971-4981	Endogenous	substance[265]	giv[265]	coref	29-20[0_265]
29-2	4982-4989	ethanol	substance[265]	giv[265]	_	_
29-3	4990-4992	is	_	_	_	_
29-4	4993-5001	supposed	_	_	_	_
29-5	5002-5004	to	_	_	_	_
29-6	5005-5014	originate	_	_	_	_
29-7	5015-5019	from	_	_	_	_
29-8	5020-5030	intestinal	abstract[267]	new[267]	_	_
29-9	5031-5040	bacterial	substance|abstract[267]	new|new[267]	_	_
29-10	5041-5049	activity	abstract[267]	new[267]	_	_
29-11	5050-5053	via	abstract[267]	new[267]	_	_
29-12	5054-5066	fermentation	abstract[267]|substance[268]	new[267]|new[268]	_	_
29-13	5067-5069	of	abstract[267]|substance[268]	new[267]|new[268]	_	_
29-14	5070-5083	carbohydrates	abstract[267]|substance[268]|substance	new[267]|new[268]|giv	coref	29-31
29-15	5084-5085	,	abstract[267]|substance[268]	new[267]|new[268]	_	_
29-16	5086-5088	i.	abstract[267]|substance[268]	new[267]|new[268]	_	_
29-17	5089-5091	e.	abstract[267]|substance[268]	new[267]|new[268]	_	_
29-18	5092-5093	,	abstract[267]|substance[268]	new[267]|new[268]	_	_
29-19	5094-5100	breath	abstract[267]|substance[268]|abstract|abstract[272]	new[267]|new[268]|giv|new[272]	coref	31-7[290_272]
29-20	5101-5108	ethanol	abstract[267]|substance[268]|substance|abstract[272]	new[267]|new[268]|giv|new[272]	coref	31-13[291_0]
29-21	5109-5117	increase	abstract[267]|substance[268]|abstract[272]	new[267]|new[268]|new[272]	_	_
29-22	5118-5120	is	_	_	_	_
29-23	5121-5124	due	_	_	_	_
29-24	5125-5127	to	_	_	_	_
29-25	5128-5131	the	event[273]	giv[273]	coref	30-2[278_273]
29-26	5132-5138	intake	event[273]	giv[273]	_	_
29-27	5139-5143	with	event[273]	giv[273]	_	_
29-28	5144-5154	subsequent	event[273]|substance[274]	giv[273]|new[274]	_	_
29-29	5155-5164	digestion	event[273]|substance[274]	giv[273]|new[274]	_	_
29-30	5165-5167	of	event[273]|substance[274]	giv[273]|new[274]	_	_
29-31	5168-5181	carbohydrates	event[273]|substance[274]|substance	giv[273]|new[274]|giv	_	_
29-32	5182-5185	and	event[273]|substance[274]	giv[273]|new[274]	_	_
29-33	5186-5189	the	event[273]|substance[274]|object[276]	giv[273]|new[274]|new[276]	coref	30-25[284_276]
29-34	5190-5200	intestinal	event[273]|substance[274]|object[276]	giv[273]|new[274]|new[276]	_	_
29-35	5201-5211	microbiota	event[273]|substance[274]|object[276]	giv[273]|new[274]|new[276]	_	_
29-36	5212-5213	.	_	_	_	_

#Text=While the carbohydrate intake at lunch was quite similar in both groups , postprandial hyperglycemia was not and even subtle differences with respect to the intestinal microbiota between T1DM patients and controls have to be considered .
30-1	5214-5219	While	_	_	_	_
30-2	5220-5223	the	event[278]	giv[278]	_	_
30-3	5224-5236	carbohydrate	substance|event[278]	new|giv[278]	_	_
30-4	5237-5243	intake	event[278]	giv[278]	_	_
30-5	5244-5246	at	event[278]	giv[278]	_	_
30-6	5247-5252	lunch	event[278]|event	giv[278]|giv	_	_
30-7	5253-5256	was	_	_	_	_
30-8	5257-5262	quite	_	_	_	_
30-9	5263-5270	similar	_	_	_	_
30-10	5271-5273	in	_	_	_	_
30-11	5274-5278	both	person[280]	new[280]	_	_
30-12	5279-5285	groups	person[280]	new[280]	_	_
30-13	5286-5287	,	_	_	_	_
30-14	5288-5300	postprandial	abstract[281]	giv[281]	_	_
30-15	5301-5314	hyperglycemia	abstract[281]	giv[281]	_	_
30-16	5315-5318	was	_	_	_	_
30-17	5319-5322	not	_	_	_	_
30-18	5323-5326	and	_	_	_	_
30-19	5327-5331	even	abstract[282]	new[282]	_	_
30-20	5332-5338	subtle	abstract[282]	new[282]	_	_
30-21	5339-5350	differences	abstract[282]	new[282]	_	_
30-22	5351-5355	with	abstract[282]	new[282]	_	_
30-23	5356-5363	respect	abstract[282]|abstract[283]	new[282]|giv[283]	ana	31-3[0_283]
30-24	5364-5366	to	abstract[282]|abstract[283]	new[282]|giv[283]	_	_
30-25	5367-5370	the	abstract[282]|abstract[283]|object[284]	new[282]|giv[283]|giv[284]	_	_
30-26	5371-5381	intestinal	abstract[282]|abstract[283]|object[284]	new[282]|giv[283]|giv[284]	_	_
30-27	5382-5392	microbiota	abstract[282]|abstract[283]|object[284]	new[282]|giv[283]|giv[284]	_	_
30-28	5393-5400	between	abstract[282]|abstract[283]|object[284]	new[282]|giv[283]|giv[284]	_	_
30-29	5401-5405	T1DM	abstract[282]|abstract[283]|object[284]|abstract|person[286]|abstract[287]	new[282]|giv[283]|giv[284]|giv|giv[286]|giv[287]	coref|coref	31-21|31-21[294_286]
30-30	5406-5414	patients	abstract[282]|abstract[283]|object[284]|person[286]|abstract[287]	new[282]|giv[283]|giv[284]|giv[286]|giv[287]	_	_
30-31	5415-5418	and	abstract[282]|abstract[283]|object[284]|abstract[287]	new[282]|giv[283]|giv[284]|giv[287]	_	_
30-32	5419-5427	controls	abstract[282]|abstract[283]|object[284]|abstract[287]|event	new[282]|giv[283]|giv[284]|giv[287]|giv	_	_
30-33	5428-5432	have	_	_	_	_
30-34	5433-5435	to	_	_	_	_
30-35	5436-5438	be	_	_	_	_
30-36	5439-5449	considered	_	_	_	_
30-37	5450-5451	.	_	_	_	_

#Text=Altogether , this may have caused a slightly more pronounced increase of postprandial ethanol with higher peak ethanol concentrations in T1DM patients .
31-1	5452-5462	Altogether	_	_	_	_
31-2	5463-5464	,	_	_	_	_
31-3	5465-5469	this	abstract	giv	_	_
31-4	5470-5473	may	_	_	_	_
31-5	5474-5478	have	_	_	_	_
31-6	5479-5485	caused	_	_	_	_
31-7	5486-5487	a	abstract[290]	giv[290]	_	_
31-8	5488-5496	slightly	abstract[290]	giv[290]	_	_
31-9	5497-5501	more	abstract[290]	giv[290]	_	_
31-10	5502-5512	pronounced	abstract[290]	giv[290]	_	_
31-11	5513-5521	increase	abstract[290]	giv[290]	_	_
31-12	5522-5524	of	abstract[290]	giv[290]	_	_
31-13	5525-5537	postprandial	abstract[290]|substance[291]	giv[290]|giv[291]	coref	32-1[295_291]
31-14	5538-5545	ethanol	abstract[290]|substance[291]	giv[290]|giv[291]	_	_
31-15	5546-5550	with	abstract[290]|substance[291]	giv[290]|giv[291]	_	_
31-16	5551-5557	higher	abstract[290]|substance[291]|animal[292]	giv[290]|giv[291]|giv[292]	_	_
31-17	5558-5562	peak	abstract[290]|substance[291]|animal[292]	giv[290]|giv[291]|giv[292]	_	_
31-18	5563-5570	ethanol	abstract[290]|substance[291]|animal[292]	giv[290]|giv[291]|giv[292]	_	_
31-19	5571-5585	concentrations	abstract[290]|substance[291]|animal[292]	giv[290]|giv[291]|giv[292]	_	_
31-20	5586-5588	in	abstract[290]|substance[291]|animal[292]	giv[290]|giv[291]|giv[292]	_	_
31-21	5589-5593	T1DM	abstract[290]|substance[291]|animal[292]|abstract|person[294]	giv[290]|giv[291]|giv[292]|giv|giv[294]	coref	32-10[296_294]
31-22	5594-5602	patients	abstract[290]|substance[291]|animal[292]|person[294]	giv[290]|giv[291]|giv[292]|giv[294]	_	_
31-23	5603-5604	.	_	_	_	_

#Text=Elevated endogenous ethanol was also already previously detected in diabetic patients .
32-1	5605-5613	Elevated	substance[295]	giv[295]	_	_
32-2	5614-5624	endogenous	substance[295]	giv[295]	_	_
32-3	5625-5632	ethanol	substance[295]	giv[295]	_	_
32-4	5633-5636	was	_	_	_	_
32-5	5637-5641	also	_	_	_	_
32-6	5642-5649	already	_	_	_	_
32-7	5650-5660	previously	_	_	_	_
32-8	5661-5669	detected	_	_	_	_
32-9	5670-5672	in	_	_	_	_
32-10	5673-5681	diabetic	person[296]	giv[296]	_	_
32-11	5682-5690	patients	person[296]	giv[296]	_	_
32-12	5691-5692	.	_	_	_	_
